Focused On-demand Library for Ephrin type-A receptor 5

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

P54756

UPID:

EPHA5_HUMAN

Alternative names:

Brain-specific kinase; EPH homology kinase 1; EPH-like kinase 7

Alternative UPACC:

P54756; Q7Z3F2

Background:

Ephrin type-A receptor 5 (EPHA5), also known as Brain-specific kinase, EPH homology kinase 1, and EPH-like kinase 7, is a receptor tyrosine kinase that engages in bidirectional signaling via GPI-anchored ephrin-A family ligands. This interaction is pivotal for axon guidance during development, influencing the formation of the retinotectal, entorhino-hippocampal, and hippocamposeptal pathways. Moreover, EPHA5, in concert with EFNA5, contributes to synaptic plasticity in the adult brain by regulating synaptogenesis. Its role extends to the pancreatic islet cells, where it mediates glucose-stimulated insulin secretion.

Therapeutic significance:

Understanding the role of Ephrin type-A receptor 5 could open doors to potential therapeutic strategies.